Catalyst

Slingshot members are tracking this event:

Esperion Therapeutics set to launch global cardiovascular outcomes trial (CVOT) on bempedoic acid on major cardiovascular events for high-risk cardiovascular disease (CVD) patients by first half of 2019

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
ESPR Community voting in process
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Global Cardiovascular Outcomes Trial, Bempedoic Acid, Cardiovascular Disease